Literature DB >> 23537378

Oral information about side effects of endocrine therapy for early breast cancer patients at initial consultation and first follow-up visit: an online survey.

Gero Luschin1, Marion Habersack.   

Abstract

This study was initiated to identify how physicians inform women about specific side effects of endocrine therapy for early breast cancer. It is recommended that women with early breast cancer receive endocrine treatment for at least 5 years. Although this medication is an important step in curing breast cancer, continued application by patients is far below 100%; 30-50% of all women prematurely end their prescribed therapy. In an online survey, physicians specializing in treating breast cancer (members of the Austrian Breast and Colorectal Cancer Study Group, ABCSG) were asked about their practice of informing patients about potential side effects of endocrine therapy for breast cancer. Two hundred and five members of the ABCSG completed the online questionnaire. The physicians indicated that patients were primarily informed regarding joint pain/muscle pain and flushes/sleep disturbances during the initial consultation as well as during the first follow-up visit. Patients were informed considerably less regarding side effects that influence quality-of-life areas, such as pain during intercourse, reduced orgasm capability, and hair loss. During the initial consultation, and during first follow-up visit, patients are not uniformly and are insufficiently informed about substantial side effects of endocrine therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23537378     DOI: 10.1080/10410236.2012.743096

Source DB:  PubMed          Journal:  Health Commun        ISSN: 1041-0236


  3 in total

Review 1.  Oral Endocrine Therapy Nonadherence, Adverse Effects, Decisional Support, and Decisional Needs in Women With Breast Cancer.

Authors:  Jennifer L Milata; Julie L Otte; Janet S Carpenter
Journal:  Cancer Nurs       Date:  2018 Jan/Feb       Impact factor: 2.592

2.  Race and Patient-reported Symptoms in Adherence to Adjuvant Endocrine Therapy: A Report from the Women's Hormonal Initiation and Persistence Study.

Authors:  Vanessa B Sheppard; Arnethea L Sutton; Alejandra Hurtado-de-Mendoza; Jun He; Bassam Dahman; Megan C Edmonds; Mary Helen Hackney; Mahlet G Tadesse
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-01-29       Impact factor: 4.254

3.  Comprehensive analysis of the lncRNA‑associated competing endogenous RNA network in breast cancer.

Authors:  Jing-Jing Wang; Yue-Qing Huang; Wei Song; Yi-Fan Li; Han Wang; Wen-Jie Wang; Min Huang
Journal:  Oncol Rep       Date:  2019-10-15       Impact factor: 3.906

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.